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With advances in diagnostic imaging, small renal
masses are being detected earlier and with increased fre-
quency. The differential diagnosis of a small renal mass
is extensive and includes a cyst, infarction, focal infec-
tion, angiomyolipoma, lymphoma, metastatic neoplasm,
oncocytoma, renal cell carcinoma, and pseudotumor [1].
Differentiation is based on the clinical history and spe-
cific imaging findings.
There are three renal cystic diseases that are strongly
associated with solid renal masses. Knowledge of these
diseases and the renal neoplasms with which they are
associated aids the proper diagnosis and treatment of
these patients. In this article, we review acquired cystic
kidney disease (ACKD), von Hippel-Lindau disease
(VHL), and tuberous sclerosis (TS) and suggest the ap-
propriate diagnostic evaluation when a solid renal mass
is discovered.
Acquired cystic kidney disease
ACKD is characterized by the formation of multiple re-
nal cysts in patients with end-stage renal disease who
have no history of hereditary cystic disease [2]. Al-
though the term ACKD was initially applied to the de-
velopment of multiple cysts in patients on long-term
hemodialysis [3–5], ACKD also occurs in patients on
peritoneal dialysis and in patients prior to the start of
dialysis [6].
There are three commonly used nomenclatures for
this disease: acquired cystic disease of the kidneys, ac-
quired cystic kidney disease, and acquired renal cystic
disease. The occurence of ACKD in patients with renal
failure was first noted by Simon in 1847 [7]. However,
it was not until 1977, that Dunnill et al. described ‘‘ac-
quired cystic disease of the kidneys’’ in hemodialysis
patients [4]. They reported an autopsy series in which
46.6% of patients on long-term hemodialysis developed
renal cysts. They also noted that these patients had two
significant complications, perinephric hemorrhage and
renal tumor formation. ACKD is now a well-recognized
clinical entity with the potential complications of renal
cyst hemorrhage, cyst infection, matrix stone formation,
renal cell carcinoma, and retroperitoneal bleeding [8–
10].
End-stage renal disease (ESRD) is essential to the
development of ACKD. Prior to the initiation of dialy-
sis, as many as 8–22% of uremic patients develop
ACKD [11–14]. Cyst formation is linked to the dura-
tion of dialysis. After 1–3 years of dialysis, the preva-
lence of ACKD is 10–20%, rising to 40–60% after 3–5
years, and to more than 90% after 5–10 years of dialysis
[8, 15]. Before the advent of hemodialysis, these pa-
tients had a rapidly fatal disease. It is likely that cyst
formation is promoted by dialysis because their im-
proved survival gives these patients a greater opportu-
nity to develop cysts [16–18].
Neither the type of dialysis nor the nature of the
underlying renal disease is a factor in the development
of renal cyst formation. ACKD affects patients on he-
modialysis and peritoneal dialysis equally [8, 11, 16,
19]. Any type of renal disease leading to ESRD may be
associated with ACKD [9]. It has been reported that
diabetic nephropathy is associated with a lower inci-
dence of ACKD [6, 11], but this may be due to the
shorter survival of these patients on dialysis. However,
analgesic nephropathy and arteriosclerotic nephroscle-
rosis tend to be more commonly associated with ACKD
[6, 11]. Men and women have a similar prevalence of
ACKD, but the severity of cystic transformation is
greater in men than in women [6, 8, 9, 11]. Patient age
is not a factor, but there may be racial differences be-
cause African-Americans are more prone to developing
cysts than European-Americans [6, 8, 9].
The natural history of ACKD after renal transplan-
tation is unclear, and there are conflicting reports on the
effect of renal transplantation. Recent data suggest that
ACKD often persists after renal transplantation and that
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Fig. 1. Acquired cystic kidney disease. Con-
trast-enhanced CT shows multiple bilateral re-
nal cysts in a patient with ESRD.
its persistence is unrelated to the duration of the func-
tioning renal graft [9, 15, 20]. Therefore, renal trans-
plant recipients are still at risk for ACKD and its com-
plications, and this risk increases if the renal transplant
function is impaired [8, 9, 15, 21].
Renal pathology
ACKD is characterized by multiple bilateral small cysts
involving both the renal cortex and medulla. On gross
examination, the acquired cysts are small, with more
than 90% having a diameter less than 0.6 cm, although
some may reach a diameter of 2.5–3.0 cm [6, 9, 16].
Affected kidneys are usually small, reflecting ESRD,
but with cyst formation, the kidneys enlarge [9, 16]. On
histological examination, cysts are typically lined with
a single layer of cuboidal or columnar epithelium, al-
though some are lined with multilayered epithelium
with papillary projections [9, 16].
Renal neoplasms occur with an increased frequency
in patients with ACKD [4, 8]. Evidence suggests that
renal cyst and renal tumor formation are interrelated.
There appears to be a continuum from single-layered
epithelial cysts, to multilayered epithelial cysts, to renal
cell carcinomas [9, 18]. Tumors can be multiple and
bilateral and often arise from cyst walls. However, renal
neoplasms can also occur in areas uninvolved by cysts
[16].
Factors causing renal cyst and tumor formation in
ESRD are unknown. It is postulated that, with progres-
sive destruction of functioning renal tissue, cystogenic
substances accumulate and cause hypertrophy and hy-
perplasia of epithelial cells [9, 16]. Focal proliferation
of tubular epithelium, oxalate crystal deposition, and
surrounding interstitial fibrosis may then result in cystic
dilatation of renal tubules [9, 16].
Imaging features
To establish the diagnosis of ACKD, polycystic kidney
disease must be excluded, and at least 3–5 renal cysts
must be visible on an imaging modality, usually ultra-
sound, computed tomography (CT), or magnetic reso-
nance (MR) [6, 8, 9, 11, 19, 22]. Depending on the
duration of the disease, the radiographic features of
ACKD vary widely. Often, no cystic changes are radio-
graphically apparent during the first 3 years of dialysis
[19]. Pathologic examination has shown that micro-
scopic cysts are often present during the first few years
of dialysis but are too small to be detected radiograph-
ically. With time, the cysts grow, enlarging the kidneys
and distorting the renal architecture. Ultimately, with
progression, these kidneys may resemble those of pa-
tients with autosomal dominant polycystic kidney dis-
ease [19].
The findings of ACKD on an abdominal radiograph
are nonspecific. The kidneys are usually small, the result
of chronic renal disease, and cyst wall calcifications can
sometimes be detected. Excretory urography is not uti-
lized because these patients have minimal or no renal
function.
Ultrasound is useful in the diagnosis and evaluation
of ACKD. The affected kidneys have multiple cysts and
are usually small with increased echogenicity [16, 19].
The cysts may cause renal enlargement, and with time
the sonographic appearance may resemble autosomal
dominant polycystic kidney disease [17, 19]. Ultra-
sound can also be utilized to help further characterize
an indeterminate renal mass discovered on CT.
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Fig. 2. Acquired cystic kidney disease. Unenhanced CT re-
veals a high-attenuation, left renal mass; attenuation re-
mained unchanged after intravenous contrast administration.
Findings are consistent with a hemorrhagic cyst. Also note
intraperitoneal fluid from the patient’s peritoneal dialysis.
Fig. 3. Acquired cystic kidney disease. Contrast-enhanced
CT shows innumerable renal cysts with an associated left
retroperitoneal bleed.
Fig. 4. Acquired cystic kidney disease. Contrast-enhanced
CT demonstrates multiple bilateral renal cysts and dystropic
calcifications. A large subcapsular hematoma is seen around
the left kidney with the fluid in the perinephric space, indi-
cating a perinephric component.
CT is the most sensitive method for detecting
ACKD. On CT, the kidneys are studded with multiple
small cysts (Fig. 1), and dystrophic cyst wall calcifica-
tion is common [16]. Iodinated intravascular contrast
medium may be used if the patient is on dialysis. How-
ever, the referring physician should be alerted because
the patient’s dialysis schedule may need to be altered to
remove the salt load from the administration of intra-
vascular contrast media.
On MR imaging, renal cysts present as multiple,
well-defined, nonenhancing, homogeneous masses with
low signal intensity on T1-weighted images [23]. MR
imaging is not necessary to diagnose ACKD, but it can
be helpful in selected patients. MR imaging can be used
in patients in whom iodinated intravascular contrast me-
dium is contraindicated; and it can also help further
characterize an indeterminate renal mass discovered on
CT.
Complications
The majority of patients with ACKD are asymptomatic
[8–10]. The most common presenting complaint is
flank pain due to spontaneous hemorrhage. As many as
50% of patients with ACKD may develop hemorrhagic
cysts (Fig. 2) [9]. Hemorrhage into cysts probably oc-
curs because unsupported sclerotic vessels in the cyst
walls rupture. Bleeding may also be promoted by sys-
temic heparinization during dialysis and platelet dys-
function due to uremia [9–12]. Bleeding may be con-
fined to the cysts but can also extend into the renal
collecting system or the retroperitoneum (Fig. 3). Ex-
tension of hemorrhage into the renal collecting system
can cause painful gross hematuria. Extension into the
subcapsular or perinephric spaces (Fig. 4) can cause
flank pain and may be extensive enough to cause a fall
in hematocrit.
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Fig. 5. Acquired cystic kidney disease. Contrast-en-
hanced CT reveals a solid mass in the right posterior
kidney that is a pathologically proven renal cell carci-
noma.
The other major complication in ACKD is renal tu-
mor formation (Fig. 5). In patients with ESRD, the in-
cidence of renal cell carcinoma is increased over that of
the general population [8, 18, 24]. This risk appears to
rise even more in the presence of ACKD [8, 22]. In fact,
more than 80% of patients with ESRD who develop
renal cell carcinoma have ACKD [8]. In dialysis pa-
tients, renal cell carcinoma presents at an earlier age
than in the general population, and it occurs seven times
more commonly in men than in women [8, 9]. Often
these neoplasms are asymptomatic, but sometimes pa-
tients present with gross hematuria, flank pain, fever,
erythrocytosis, or hypercalcemia [9, 25].
It is generally accepted that the incidence of renal
cell carcinoma increases in ACKD; however, the degree
of increase is controversial. Some investigations have
reported an increase in the incidence of renal cancer of
greater than 100-fold in dialysis patients over that of the
general population [8, 11]. However, such data do not
correlate well with clinical experience. Recent reports
have suggested that the annual incidence of invasive or
metastatic renal cell carcinoma, that is, ‘‘clinically sig-
nificant’’ renal cell carcinoma, among dialysis patients
is three to six times greater than that of the general pop-
ulation [2, 9, 25]. These data are consistent with a pop-
ulation-based study conducted by the Michigan Kidney
Registry in which there was a fivefold increase in the
incidence of invasive renal cell carcinoma in dialysis
patients as compared with the general population from
the same geographic area [9, 25].
Diagnostic evaluation
Some investigators have recommended periodic screen-
ing of asymptomatic dialysis patients because of the risk
of developing renal cell carcinoma [5, 13, 14, 18, 26–
28]. Most have recommended screening beginning after
completion of the third year of dialysis because the fre-
quency of ACKD visible on imaging studies signifi-
cantly increases at this time [8, 9, 19]. In patients un-
dergoing long-term dialysis, the value of routine
screening has been questioned because there is insuffi-
cient data to assess the effects of screening on patient
outcome [9, 15, 25, 29].
In the United States, the overall mortality in dia-
lyzed ESRD patients is high. Patients aged 30–49 years
have a life expectancy of 5–10 years, whereas patients
50 years and older have a life expectancy of only 1.5–
6 years [9]. These patients die from numerous causes
including cardiac disease, cerebrovascular accidents, in-
fection, and withdrawal from dialysis. Malignancy is
not a frequently reported cause of death [2]. Therefore,
early detection and treatment seems unlikely to signifi-
cantly improve survival of dialysis patients.
Using a quantitative method of decision analysis,
Sarasin et al. assessed the value of routine screening of
dialysis patients [30]. Their analysis concluded that rou-
tine screening of the entire ESRD population for ACKD
and renal malignancy is not justifiable. The strategy of
performing either CT or ultrasound examinations every
3 years on all dialysis patients and annually on patients
found to have cysts was compared with a strategy of
seeking cysts and cancer only if clinically suspected.
For patients with a life expectancy of 25 years, screen-
ing with either CT or ultrasound examinations may de-
crease cancer death by half and improve the life expec-
tancy by as much as a 1.6 years [30]. However, age and
comorbid disease substantially limit life expectancy for
the majority of patients beginning renal replacement
therapy. For such patients, an ACKD screening program
prolongs average life expectancy only by days [30]. In
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fact, under certain circumstances, an ACKD screening
program may even shorten survival of older dialysis pa-
tients who are at increased surgical risk [2, 9, 30]. That
is, in the presence of ACKD, if the false-positive rate
of CT as a test for cancer were 10%, screening would
shorten survival for patients aged 64 and older. In the
United States, the median age of patients beginning di-
alysis is 62 years [9, 30]. Thus, screening could actually
shorten the average survival of almost half of ESRD
patients in the United States.
Although universal screening of all ESRD patients
is not justified, a screening program for selected patients
may be beneficial [9, 30]. Primary considerations for
the selection of such patients would include age, general
medical condition, life expectancy, and known risk fac-
tors, i.e., prolonged dialysis, presence of ACKD, and
male gender.
Because there is an increased incidence of renal cell
carcinoma in patients with ESRD, the native kidneys of
potential transplant candidates should be imaged for re-
nal tumors prior to surgery [2, 21]. However, even
though renal transplant recipients remain at risk for
ACKD and its complications, the number of case reports
of renal cancer developing in the native kidneys of these
patients is too small to justify annual screening [2]. Be-
cause transplant recipients often undergo ultrasound
evaluation of the transplant kidney, some have advo-
cated routinely scanning the native kidneys during this
examination [8].
Treatment
Without complications, ACKD requires no treatment.
Patients with symptomatic hemorrhagic cysts, i.e., flank
pain and hematuria, can be treated with analgesics.
Large hemorrhagic cysts should be followed by serial
imaging to document resolution. Because bleeding often
subsides spontaneously, retroperitoneal hemorrhage
should be managed conservatively with bed rest, hydra-
tion, transfusion, correction of coagulation indexes, and
analgesics. Patients conservatively treated for perineph-
ric hemorrhage should also undergo serial CT scans to
exclude an underlying renal tumor as the cause of the
hemorrhage. If a patient continues to bleed despite con-
servative measures, selective angiography may localize
sites of active hemorrhage; selective embolization may
stop the bleeding and obviate the need for nephrectomy.
Renal neoplasms can pose significant management
problems. If a large renal cell carcinoma is discovered,
a nephrectomy should be performed. If a tumor is less
than 3 cm in diameter, management decisions are based
on the patient’s age, general medical condition, and life
expectancy. The potential for these small neoplasms to
metastasize is low [4, 12]. Surgery should be avoided if
the patient is a poor operative risk. If CT shows a change
in tumor size or appearance, surgical exploration should
be performed. In patients who are acceptable operative
risks, management of small (õ3 cm) renal neoplasms
is controversial. Some have advocated radical nephrec-
tomy in all of these patients, whereas others have rec-
ommended monitoring with annual CT scans [9, 11].
Because tumors are often multiple and bilateral,
there is controversy over whether only the affected kid-
ney should be resected or both kidneys should be re-
moved. In dialysis patients, the risk of developing renal
neoplasms in the remaining kidney must be weighed
against the increased morbidity and mortality of bilat-
eral nephrectomy. Complications of bilateral nephrec-
tomy include anemia resulting from the loss of endog-
enous erythropoietin, severe hypotension, and increased
dependence of dialysis. Given the risks and benefits,
preventive bilateral nephrectomy is not advised.
Renal cell carcinoma does not disqualify a potential
transplant candidate, but bilateral nephectomy has been
recommended in these patients [6, 9]. Patients with Rob-
son’s stage 1 classification can undergo transplantation
immediately, but those with stage 2 need to remain in
that stage for 1–2 years prior to renal transplantation
[6].
Von Hippel-Lindau disease
VHL is a rare inherited disorder characterized by a va-
riety of benign and malignant neoplasms throughout the
body. VHL has an autosomal dominant mode of inher-
itance with penetrance approaching 100% [31, 32]. The
most common neoplasms found in patients with VHL
are retinal angiomatosis, cerebellar hemangioblastomas,
renal cell carcinomas, and pheochromocytomas [33,
34]. Other common neoplasms include other central
nervous system hemangioblastomas; angiomas of the
liver and kidney; adenomas of the epididymis; pancre-
atic islet cell tumors; and cysts of the kidney, pancreas,
and epididymis [35–38]. Central nervous system he-
mangioblastomas are the immediate cause of death in
more than half of all affected patients, whereas renal
carcinomas account for approximately 30% of deaths
[39, 40].
Renal cell carcinoma is found in 25–45% of patients
with VHL, is bilateral in 75% of patients and multifocal
in 87% [16, 32, 37, 40, 41]. Renal tumors are usually
diagnosed in the fourth or fifth decade of life, which is
earlier than sporadic cases, which typically arise in the
sixth decade [42, 43]. The close association of VHL
with renal cell carcinoma led to the localization of the
mutant von Hippel-Lindau gene [44]. The gene for VHL
has been mapped to chromosome 3p25, a region often
detected in sporadic cases of renal cell carcinoma [45].
Multiple renal cysts occur with increased frequency
and are the most common single manifestation of VHL,
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Fig. 6. Von Hippel-Lindau disease. Contrast-
enhanced CT shows multiple pancreatic and renal
cysts in a patient with VHL.
occurring in 76% of patients [16, 37]. The cysts are
typically small and seldom cause renal enlargement.
However, uncommonly, the kidneys may enlarge and
resemble autosomal dominant polycystic kidney disease
[34]. Renal cysts may be the earliest sign of VHL, with
renal carcinoma tending to occur late in the disease [16,
34].
Renal pathology
Occurring mainly in the renal cortex, cysts are typically
multiple, bilateral, and small, ranging in size from 0.5
to 3.0 cm in diameter [16, 46]. Most cysts are lined by
simple cuboidal epithelium and are filled with clear
fluid. However, some cystic masses are really renal cell
carcinomas that have undergone cystic degeneration.
These cystic carcinomas are lined by malignant clear
cells similiar to those seen in solid tumors [16].
Renal cell carcinomas are also usually multiple, bi-
lateral, and small, with most carcinomas less than 3 cm
in diameter. Tumors often show irregular margins even
though they may have fibrous capsules. Typically, these
neoplasms are composed of moderately well-differen-
tiated clear cells; they often show hemorrhage, necrosis,
or focal capsular invasion [16].
Imaging features
Because the kidneys are usually normal in size, abdom-
inal radiographs are often normal. On excretory urog-
raphy, renal cortical cysts are seen bilaterally. The cysts
distort the renal architecture, making it difficult to di-
agnose small tumors unless they are peripheral or dis-
place the collecting system [32, 47]. Thus, excretory
urography is seldom used in the evaluation of patients
with VHL.
Ultrasound is highly sensitive for the detection of
renal cysts. Because it is readily available, relatively
inexpensive, and does not require ionizing radiation, it
is often used to detect renal cysts. Ultrasound may also
help in the evaluation of an indeterminate lesion seen
on CT. In patients with known VHL, ultrasound is of
limited use for screening because it is insensitive in de-
tecting small renal tumors.
CT is more sensitive than ultrasound in the detection
of renal masses. Furthermore, lesions can be precisely
defined, which facilitates monitoring lesion growth.
Cysts are characterized by well-defined, thin-walled,
nonenhancing, fluid attenuation masses (Fig. 6). Solid
renal masses typically have indistinct irregular tumor
margins, heterogeneity, and contrast enhancement that
is less than that seen in normal renal parenchyma (Figs.
7, 8).
MR imaging is indispensible for diagnosing and
evaluating the multiple neurological neoplasms com-
mon in patients with VHL; however, MR of the kidneys
is of limited use. Unless they alter the shape of the kid-
neys, small renal cell carcinomas can go undetected be-
cause these lesions tend to have a signal intensity similar
to that of renal parenchyma on both T1- and T2-
weighted images [23]. Gadolinium administration
greatly improves detection because enhancement of re-
nal cell carcinoma differs from that of normally en-
hancing renal parenchyma [23]. Large tumors are more
easily recognizable, tend to be more heterogeneous, and
sometimes contain areas of hyperintensity on T1- and
T2-weighted images [23].
The angiographic findings of renal cell carcinoma
in patients with VHL include well-circumscribed, mul-
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Fig. 7. Von Hippel-Lindau disease. Contrast-en-
hanced CT demonstrates a huge left renal mass
and a smaller solid mass in the right kidney. On
pathological examination, both were renal adeno-
carcinoma. Also note innumerable pancreatic
cysts.
Fig. 8. Von Hippel-Lindau disease. A Contrast-
enhanced CT reveals a small left renal mass.
B Images obtained 12 months later show interval
growth of this renal cell carcinoma.
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ticentric lesions with neovascularity [32, 40]. Even se-
lective renal angiography does not always detect small
renal tumors, nor can it reliably differentiate benign
from malignant lesions [40]. Therefore, angiography is
seldom used for the detection or exclusion of renal cell
carcinoma. Renal angiography is primarily limited to
vascular mapping prior to partial nephrectomy or tumor
enucleation [40].
Diagnostic evaluation
To find renal cell carcinomas while they are still small
and before they have metastasized, patients with VHL
should be screened for asymptomatic renal tumors.
Some have suggested MR imaging as a potentially use-
ful screening examination [31]; however, CT is the most
frequently used method of screening because it dem-
onstrates more renal lesions and is less expensive than
MR [41]. Most have advocated annual screening of all
patients with VHL even in the absence of abdominal
symptoms [34, 42, 48]. Some have recommended
screening every 2–4 years if the initial CT examination
is normal [16, 45].
Because VHL has an autosomal dominant mode of
inheritance, half of the offspring of an affected patient
may be expected to develop the disease. Periodic
screening of at-risk family members is essential. There
is no consensus as to the age at which screening should
commence, the frequency with which it should be per-
formed, or the modality that should be used. Some have
advocated beginning screening at preschool age, with
repeat scans every 2–3 years up to age 20 years and
then annually into the sixth or seventh decade [38]. Oth-
ers have recommended initial scanning when patients
are 18–20 years old because most disease manifesta-
tions become apparent at that age and repeat scans every
1–5 years, depending on the imaging findings and the
disease pattern in the family [16, 39]. The recommended
screening modality is CT, but abdominal ultrasound
may be used for patients õ16 years old [35]. If an at-
risk family member is diagnosed with VHL, the patient
should be followed more closely.
Treatment
Renal cysts are usually asymptomatic and require no
therapy. However, apparent cysts are sometimes renal
cell carcinomas that have undergone cystic degenera-
tion. Therefore, a change in any renal mass is an indi-
cation for further evaluation and possible surgery. Be-
cause the lesions are sometimes smaller than 1 cm,
distinction between small renal cysts and carcinomas
often can not be made. If CT identifies a small indeter-
minate mass, annual CT examinations using narrow col-
limation are recommended [16, 37].
Renal cell carcinoma requires surgical management.
However, because renal neoplasms are often bilateral
and multicentric in patients with VHL, treatment has
been controversial. Surgical alternatives include renal-
sparing tumor enucleation, partial nephectomy, and bi-
lateral nephrectomy with hemodialysis or transplanta-
tion [35, 38, 42, 49, 50]. Standard nephrectomy would
eventually lead to many anephric patients. With renal-
sparing enucleation or partial nephectomy, patients can
live without dialysis or transplantation, but there is a
75% chance of recurrence within the same or opposite
kidney [38]. The risks and complications of bilateral
nephrectomy must be weighed against the risk of re-
current renal cell carcinoma. A conservative surgical
approach has been adopted because renal-conserving
procedures preserve renal function and spare patients
the morbidity and mortality associated with hemodial-
ysis and transplantation [40–42, 48–51]. In patients in
whom bilateral nephrectomies are unavoidable, a delay
in renal transplantation for at least 1 year has been ad-
vocated [39, 41].
Tuberous sclerosis
TS, formerly known as Bourneville’s disease, is a ge-
netically transmitted neurocutaneous disorder charac-
terized by mental retardation, seizures, and cutaneous
lesions. TS has an autosomal dominant mode of inher-
itance, with a high penetrance and variable expressivity
[52]. In addition, some cases are sporadic and appar-
ently the result of spontaneous new mutations [16, 53].
This disorder is characterized by benign congenital tu-
mors (hamartomas) composed of normal tissues but in
abnormal quantities, arrangement, maturation, and
growth. These hamartomas occur in the brain (cortical
tubers), retina, skin, heart (rhabdomyomas), bone, lung,
liver, adrenal gland, pancreas, and kidney (angiomyoli-
pomas) [52–54].
The most common of these hamartomas is renal an-
giomyolipomas, which has an incidence of 70–95%
among patients with TS [16]. Furthermore, the inci-
dence appears to increase with age [52, 55]. Less com-
monly known is the renal cyst formation that also occurs
in TS. Renal cysts occur less frequent than angiomyoli-
pomas and can occur alone or in conjunction with an-
giomyolipomas [54]. Rarely, renal cystic disease may
be the earliest clinical manifestation of TS in childhood
[45, 53–56].
The occurrence of both angiomyolipomas and renal
cysts is virtually diagnostic of TS. These lesions can be
unilateral and solitary but are typically multiple and bi-
lateral. Angiomyolipomas and renal cysts are usually
asymptomatic, but in some patients these lesions cause
significant problems. Angiomyolipomas may sponta-
neously bleed, and renal cysts can increase in number
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Fig. 9. Tuberous sclerosis. Contrast-enhanced
CT demonstrates multiple renal cysts and bi-
lateral fatty masses consistent with angio-
myolipomas.
and size significant enough to cause renal insufficiency
[53, 54, 57]. Five to 15 percent of TS patients develop
ESRD [45]. ESRD is more likely when renal cysts are
present (with or without angiomyolipomas) than when
angiomyolipomas are present alone [57]. Whether or
not there is an increased incidence of renal cell carci-
noma is controversial [16, 45, 53, 57].
Renal pathology
Renal cysts vary in size, from microscopic to 3 cm in
diameter. These cysts, which are probably of tubular
origin, diffusely involve the kidneys. The cysts usually
have an unique epithelial lining composed of large cells
with eosinophilic cytoplasm and prominent hyperchro-
matic nuclei [16, 54, 57]. Because renal cysts may be
the first clinical manifestation of TS, these unique his-
tological findings can strongly suggest the diagnosis.
Angiomyolipomas are benign nonencapsulated
masses consisting of varying amounts of abnormal
blood vessels, smooth muscle, and mature fat. The ma-
jority of angiomyolipomas are small, less than 1 cm in
diameter [52]. Hemorrhage and necrosis are common,
and calcifications can occur [45, 58]. Smooth muscle
cells may show hyperchromatism, pleomorphism, and
occasional mitotic figures; however, these findings are
insufficient for the diagnosis of malignancy [54, 57].
Imaging features
On abdominal radiographs, lucency suggesting fat
within an angiomyolipoma can occasionally be de-
tected. The findings on excretory urography and retro-
grade pyelography depend on the number and size of
cysts and angiomyolipomas. Findings range from nor-
mal to an appearance that mimics autosomal dominant
polycystic kidney disease. On excretory urography,
there are typically multiple nonopacifying renal masses,
with some distortion of the collecting system.
On sonographic examination, renal cysts are an-
echoic and multiple. The sonographic appearance of an
angiomyolipoma depends on its fat content. If there is
abundant fat, angiomyolipomas are hyperechoic; how-
ever, if predominately nonfatty, these cysts are indistin-
guishable from other solid tumors.
CT is the most useful imaging modality for evalu-
ating the kidneys. Renal cysts appear identical to simple
cysts, and some may contain mural calcifications (Fig.
9). If the kidneys enlarge, CT findings can be indistin-
guishable from autosomal dominant polycystic kidney
disease. However, unlike autosomal dominant polycys-
tic kidney disease, the renal cysts are usually associated
with angiomyolipomas. The key to diagnosing an an-
giomyolipoma is the demonstration of fat. Because of
its sensitivity in detecting small foci of fat, CT is the
optimal imaging modality. Fat-containing angiomyoli-
pomas have low (negative) attenuation values. How-
ever, if angiomyolipomas are predominately nonfatty or
if intramural hemorrhage obscures the fat, they are in-
distinguishable from other solid tumors.
On MR, renal cysts are seen as multiple, well-de-
fined, nonenhancing, homogeneous masses with low
signal intensity on T1-weighted images [23]. Because
they contain fat, angiomyolipomas have high signal in-
tensity on both T1- and T2-weighted images. MR im-
aging is seldom needed in the diagnosis of the renal
lesions; however, MR imaging can help further char-
acterize and evaluate an indeterminate mass discovered
on CT.
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Fig. 10. Tuberous sclerosis. A Unenhanced CT
shows angiomyolipomas and areas of increased
attenuation. B After intravenous contrast adminis-
tration, the lack of enhancement of these high at-
tenuation fluid collections indicates subcapsular
hematoma. Also note the water attenuation cysts
apparent on the enhanced images.
Renal angiography is seldom used for diagnostic
purposes but can be helpful in the evaluation of com-
plications. If performed, multiple avascular zones cor-
responding to renal cysts can be seen. The angiographic
appearance of angiomyolipomas is variable depending
on the amount of angiomatous tissue. Most angiomy-
olipomas are recognized by their small aneurysms and
whorled nephrogram of neovascularity [16, 59].
Diagnostic evaluation
In patients without other stigmata of TS, angiomyolipo-
mas can provide a clue to the diagnosis of TS because
angiomyolipomas do not occur in other renal cystic dis-
eases. Careful examination using CT with narrow col-
limation can often show small fat-containing angiomyo-
lipomas. Because angiomyolipomas are not always
present, absence of angiomyolipomas does not exclude
the diagnosis of TS. Rarely, renal cysts are the only
renal manifestation [16].
A variation on the renal cystic disease of TS is a sub-
group of patients who have severe cystic disease grossly
indistinguishable from autosomal dominant polycystic
kidney disease [54–57]. Because of this subgroup, it has
been recommended that all children presenting with the
clinical or radiological appearance of polycystic kidney
disease should receive a renal CT with narrow collimation
searching for angiomyolipomas or a renal cyst biopsy to
evaluate for hyperplastic eosinophilic epithelial lining
[54–56]. These patients should also receive a thorough
evaluation to search for other lesions of TS.
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Treatment
Renal cystic disease of TS is usually asymptomatic, and
treatment is rarely necessary. Treatment is only neces-
sary when the cysts become large and cause pain, ob-
struction, and hemorhage [54]. As renal lesions grow,
they compress and replace renal parenchyma and thus
diminish renal function. Therefore, in select cases, some
have advocated decompression of the cysts to protect
adjacent renal parenchyma from atrophy [53, 54]. Some
patients with renal cystic disease develop hypertension
and renal insufficiency progressing to ESRD. In these
patients, antihypertensive medication and dialysis may
become necessary.
Most angiomyolipomas are asymptomatic. The
main complication of angiomyolipomas is spontaneous
hemorrhage (Fig. 10). The risk of hemorrhage increases
with the size of the angiomyolipoma [60, 61]. Angio-
myolipomas associated with TS grow faster than do
sporadic angiomyolipomas [45, 60]. An actively bleed-
ing angiomyolipoma can be treated by selective angi-
ography and embolization of the intrarenal artery supply
in the tumor [53, 59]. In life-threatening bleeds that are
not amendable to angiography, surgical intervention be-
comes necessary. Functioning renal parenchyma is al-
ready compromised by replacement of the renal paren-
chyma with cysts and angiomyolipomas; therefore,
partial nephectomy or encleation should be attempted
to preserve functioning renal parenchyma. Because
large (ú4 cm) angiomyolipomas are at increased risk
of hemorrhage, they can be carefully observed, prophy-
lactically embolized, or surgically resected. Often, an
aggressive approach with selective embolization is ad-
vised for larger angiomyolipomas [61]. Cases of renal
cell carcinoma associated with TS have been reported.
Therefore, renal cancer should be suspected in cases of
renal lesions without demonstrable fat [53]. If malig-
nancy is suspected, exploratory surgery is necessary.
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